Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers

被引:22
|
作者
Vena, Gino A. [1 ]
Cassano, Nicoletta [1 ]
Coco, Valeria [2 ]
De Simone, Clara [2 ]
机构
[1] Univ Bari, Dept Biomed Sci & Human Oncol, Unit Dermatol & Venereol, I-70124 Bari, Italy
[2] Univ Cattolica Sacro Cuore, Unit Dermatol, I-00168 Rome, Italy
关键词
Antihypertensive drugs; cutaneous adverse drug reactions; drug-induced dermatitis; eczema; hydrochlorothiazide; CAPTOPRIL; DRUG; SURVEILLANCE; BRADYKININ; IRBESARTAN; ERUPTION;
D O I
10.3109/08923973.2013.797992
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cutaneous adverse drug reactions (ADRs) to antihypertensive drugs have been frequently reported. We describe a peculiar clinical pattern of cutaneous ADR, represented by an eczematous reaction induced by certain antihypertensive drugs that we observed in elderly patients. The case series consisted of 23 hypertensive patients aged 66-87 years; 19 of them were taking another drug in addition to the suspected antihypertensive medication and 15 were on polytherapy with three or more drugs to treat multiple comorbidities. The antihypertensive culprit agents were angiotensin-converting enzyme (ACE) inhibitors in 9 patients, ACE-inhibitors combined to hydrochlorothiazide (HCT) in 7 subjects, angiotensin II receptor blockers alone in 2 patients and associated with HCT in 5 cases. The cutaneous ADR was characterized by an eczematous rash that was generalized in 16 patients and localized in 7 cases, with predominant involvement of lower limbs. Such lesions developed after a latency of 4-30 months and were associated with moderate-to-severe itch, usually unresponsive to oral antihistamines. Histopathological diagnosis was available for 9 cases, confirming the presence of a spongiotic dermatitis with possible associated psoriasiform skin changes.
引用
收藏
页码:447 / 450
页数:4
相关论文
共 50 条
  • [1] Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus
    Verdecchia, Paolo
    Angeli, Fabio
    Reboldi, Gianpaolo
    JOURNAL OF HYPERTENSION, 2020, 38 (06) : 1190 - 1191
  • [2] Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers in the Treatment of Hypertension
    Benenson, Irina
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2022, 18 (05): : 586 - 587
  • [3] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis
    Lonn E.
    Current Atherosclerosis Reports, 2002, 4 (5) : 363 - 372
  • [4] Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
    Liu, Chia-Lin
    Shau, Wen-Yi
    Chang, Chia-Hsuin
    Wu, Chi-Shin
    Lai, Mei-Shu
    JOURNAL OF EPIDEMIOLOGY, 2013, 23 (05) : 344 - 350
  • [5] Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
    Boos, CJ
    Lip, GYH
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 889 - 890
  • [6] Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
    Holloway-Kew, Kara L.
    Betson, Amelia G.
    Anderson, Kara B.
    Sepetavc, Filip
    Gaston, James
    Kotowicz, Mark A.
    Liao, Wan-Hui
    Henneberg, Maciej
    Pasco, Julie A.
    CALCIFIED TISSUE INTERNATIONAL, 2022, 111 (04) : 396 - 408
  • [7] Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on peritoneal transport
    Coronel, Francisco
    KIDNEY INTERNATIONAL, 2011, 79 (01) : 136 - 137
  • [8] Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
    Kara L. Holloway-Kew
    Amelia G. Betson
    Kara B. Anderson
    Filip Sepetavc
    James Gaston
    Mark A. Kotowicz
    Wan-Hui Liao
    Maciej Henneberg
    Julie A. Pasco
    Calcified Tissue International, 2022, 111 : 396 - 408
  • [9] Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction
    Kostis, John B.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2019, 24 (04) : 397 - 397
  • [10] Are angiotensin-converting enzyme inhibitors and angiotensin 2 receptor blockers teratogenic?
    Morton, A. P.
    DIABETIC MEDICINE, 2013, 30 (10) : 1263 - 1264